A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
OncoResponse, Inc.
OncoResponse, Inc.
Melanoma Institute Australia
Region Stockholm
Kineta Inc.
The Christie NHS Foundation Trust
Immorna Biotherapeutics, Inc.
Immorna Biotherapeutics, Inc.
Dermatologic Cooperative Oncology Group
OHSU Knight Cancer Institute
Revolution Medicines, Inc.
Imperial College London
Cambridge University Hospitals NHS Foundation Trust
SpeciCare
Ardigen
Università Politecnica delle Marche
Ardigen
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Central Hospital, Nancy, France
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Instituto de Investigação em Imunologia
National Cancer Institute (NCI)
Rambam Health Care Campus
GammaCan